Theravance Biopharma (NASDAQ:TBPH) Issues Quarterly Earnings Results

Theravance Biopharma (NASDAQ:TBPH) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18), FiscalAI reports. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.78%. The company had revenue of $20.73 million during the quarter, compared to the consensus estimate of $22.49 million.

Theravance Biopharma Trading Up 0.1%

Shares of TBPH stock opened at $16.92 on Wednesday. The firm has a fifty day simple moving average of $16.82 and a two-hundred day simple moving average of $16.86. Theravance Biopharma has a 12 month low of $11.41 and a 12 month high of $21.03. The firm has a market capitalization of $872.23 million, a PE ratio of 16.75 and a beta of 0.19.

Insider Activity

In other Theravance Biopharma news, major shareholder Eli Samaha sold 37,799 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This represents a 0.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This represents a 5.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TBPH. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the last quarter. Creative Planning increased its position in shares of Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 842 shares during the last quarter. State of Wyoming lifted its position in Theravance Biopharma by 5.7% during the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock valued at $209,000 after purchasing an additional 1,019 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after buying an additional 1,020 shares in the last quarter. Finally, Royal Bank of Canada increased its holdings in shares of Theravance Biopharma by 12.1% in the 4th quarter. Royal Bank of Canada now owns 9,464 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 1,024 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. JonesTrading downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. BTIG Research downgraded shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright cut Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their target price for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $19.40.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.